Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study

Abstract Background The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety o...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jian-Xu Li, Wen-Xiang Deng, Shi-Ting Huang, Xiao-Feng Lin, Mei-Ying Long, Jie Zhang, Ting-Shi Su, Li-Qing Li, Ya-Dan Pang, Chun-Feng Liang, Hong-Mei Zhou, Hai-Yan Lu, Shi-Xiong Liang, Bang-De Xiang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2022-06-01
Ráidu:	Radiation Oncology
Fáttát:	Hepatocellular carcinoma Anti-PD1 Radiotherapy Overall survival Transcatheter arterial chemoembolization Sorafenib
Liŋkkat:	https://doi.org/10.1186/s13014-022-02075-6
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!